Paucity of functional CTL epitopes in the E7 oncoprotein of cervical cancer associated human papillomavirus type 16

Immunology and Cell Biology

Volumn 81, Issue 1, 2003, Pages 1-7

  Khammanivong, Vithagna ^a   Liu, Xiao Song ^a   Liu, Wen Jun ^a   Rodda, Stuart J ^b   Leggatt, Graham R ^a   Tindle, Robert W ^a   Frazer, Ian H ^a   Fernando, Germain J P ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Mimotopes Pty Ltd   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

CTL; Cytotoxic T lymphocyte epitope determination; ELISPOT; Human papillomavirus; Peptides; Tumour; Vaccines

Indexed keywords

EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; ONCOPROTEIN; TUMOR ANTIGEN; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOLECULAR SIZE; MOUSE; NONHUMAN; TRANSGENIC MOUSE; TUMOR IMMUNITY; UTERINE CERVIX CANCER; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS MUTATION; VIRUS SURVIVAL; WART VIRUS;

ANIMALS; EPITOPES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MICE; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS;

ANIMALIA; CANCER VIRUS; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES; MUS MUSCULUS; PAPOVAVIRIDAE;

EID: 0037324366     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.2003.01130.x     Document Type: Article

References (29)

1. Harty JT, Tvinnereim AR, White DW. CD8+ T cell effector mechanisms in resistance to infection. Annu. Rev. Immunol. 2000; 18: 275-308.
2. Zinkernagel RM, Bachmann MF, Kundig TM et al. On immunological memory. Annu. Rev. Immunol. 1996; 14: 333-67.
3. Sedlik C, Dadaglio G, Saron MF et al. In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity. J. Virol. 2000; 74: 5769-75.
4. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991; 351: 290-6.
5. Amaro D, Houbiers JG, Drijfhout JW et al. A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs. Hum. Immunol. 1995; 43: 13-18.
6. Feltkamp MC, Smits HL, Vierboom MP et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 1993; 23: 2242-9.
7. Li H, Natarajan K, Malchiodi EL, Margulies DH, Mariuzza RA. Three-dimensional structure of H-2Dd complexed with an immunodominant peptide from human immunodeficiency virus envelope glycoprotein 120. J. Mol. Biol. 1998; 283: 179-91.
8. Fernando GJ, Stewart TJ, Tindle RW, Frazer IH. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. J. Immunol. 1998; 161: 2421-7.
9. Fernando GJ, Khammanivong V, Leggatt GR, Liu WJ, Frazer IH. The number of long-lasting functional memory CD8+ T cells generated depends on the nature of the initial nonspecific stimulation. Eur. J. Immunol. 2002; 32: 1541-9.
10. Fernando GJ, Murray B, Zhou J, Frazer IH. Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. Clin. Exp. Immunol. 1999; 115: 397-403.
11. Koller BH, Marrack P, Kappler JW, Smithies O. Normal development of mice deficient in beta 2M, MHC dass I proteins, and CD8+ T cells. Science 1990; 248: 1227-30.
12. Kontgen F, Suss G, Stewart C, Steinmetz M, Bluethmann H. Targeted disruption of the MHC class II Aa gene in C57BL/6 mice. Int. Immunol. 1993; 5: 957-64.
13. Fernando GJ, Stewart TJ, Tindle RW, Frazer IH. Vaccine-induced Th1-type responses are dominant over Th2-type responses in the short term whereas pre-existing Th2 responses are dominant in the longer term. Scand. J. Immunol. 1998; 47: 459-65.
14. Miyahira Y, Murata K, Rodriguez D et al. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J. Immunol. Meth. 1995; 181: 45-54.
15. Chen LP, Thomas EK, Hu SL, Hellstrom I, Hellstrom KE. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc. Natl Acad. Sci. USA 1991; 88: 110-14.
16. Ressing ME, Sette A, Brandt RM et al. Human CTL epitopes encoded by human papillomavirus type 16, E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol. 1995; 154: 5934-43.
17. Bauer M, Wagner H, Lipford GB. HPV type 16 protein E7 HLA-A2 binding peptides are immunogenic but not processed and presented. Immunol. Lett. 2000; 71: 55-9.
18. Vitiello A, Marchesini D, Furze J, Sherman LA, Chesnut RW. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 1991; 173: 1007-15.
19. Czerkinsky C, Andersson G, Ekre HP et al. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J. Immunol. Meth. 1988; 110: 29-36.
20. Murali-Krishna K, Altman JD, Suresh M et al. Counting antigen-specific CD8 T cells: a re-evaluation of bystander activation during viral infection. Immunity 1998; 8: 177-87.
21. Scheibenbogen C, Romero P, Rivoltini L et al. Quantitation of antigen-reactive T cells in peripheral blood by IFN-gamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J. Immunol. Meth. 2000; 244: 81-9.
22. Akerman GS, Tolleson WH, Brown KL et al. Human papillomavirus type 16, E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life span of normal human keratinocytes. Cancer Res. 2001; 61: 3837-43.
23. Gonzalez SL, Stremlau M, He X, Basile JR, Munger K. Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16, E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J. Virol. 2001; 75: 7583-91.
24. Katich SC, Zerfass-Thome K, Hoffmann I. Regulation of the Cdc25A gene by the human papillomavirus Type 16, E7 oncogene. Oncogene 2001; 20: 543-50.
25. Nees M, Geoghegan JM, Hyman Tet al. Papillomavirus type 16 oncogenes downregulate expression of interferon- responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J. Virol. 2001; 75: 4283-96.
26. Sette A, Sidney J, del Guercio MF et al. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol. Immunol. 1994; 31: 813-22.
27. Sette A, Vitiello A, Reherman B et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 1994; 153: 5586-92.
28. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 1999; 17: 51-88.
29. Tobery TW, Wang S, Wang XM et al. A simple and efficient method for the monitoring of antigen-specific T cell responses using peptide pool arrays in a modified ELISPOT assay. J. Immunol. Meth. 2001; 254: 59-66.